Connect with us
.png){kind=small}
Schedule a Consultation!
609 N Hepburn Ave Ste 106, Jupiter, FL 33458
Monday - Friday: 9:00 am - 5:00 pm | Saturday-Sunday: Closed
© NovaGenix. All Rights Reserved. | Privacy Policy | ADA Compliance | Medical Disclaimer | Maintained by Digital Resource
THE PATIENT AND ANY OTHER PERSON RESPONSIBLE FOR PAYMENT HAS A RIGHT TO REFUSE TO PAY, CANCEL PAYMENT, OR BE REIMBURSED FOR PAYMENT FOR ANY OTHER SERVICE, EXAMINATION, OR TREATMENT THAT IS PERFORMED AS A RESULT OF AND WITHIN 72 HOURS OF RESPONDING TO THE ADVERTISEMENT FOR THE FREE, DISCOUNTED FEE, OR REDUCED FEE SERVICE, EXAMINATION, OR TREATMENT.
You may still be getting your period and still know that something has changed. Sleep no longer holds through the night, a word disappears halfway through a sentence, or a hot flash interrupts a meeting. “Bioidentical” hormone therapy may help some symptoms. Some bioidentical products are FDA-approved, while others are prepared by a compounding pharmacy when a physician determines that a patient-specific formulation is clinically appropriate. Your history, symptoms, priorities, and individual risks determine which approach—if any—makes sense.
For hot flashes and night sweats, systemic menopausal hormone therapy is the most effective treatment. It can also prevent bone loss while you use it. If vaginal dryness, painful sex, or urinary symptoms are the main problem, local vaginal therapy may help without treating your whole body.
Not automatically. The word “bioidentical” describes molecular structure rather than the quality or suitability of a specific prescription. FDA-approved estradiol and micronized progesterone are bioidentical. A compounded formulation may also be prescribed when, after physician evaluation, there is a clinically appropriate reason to individualize the dosage form or ingredients.
You may be a candidate when symptoms are bothersome and your expected benefits outweigh your risks. Your age, time since menopause, uterus and bleeding history, cancer and cardiovascular history, clot risk, liver health, medications, and priorities all matter. Symptoms alone do not automatically mean you need hormones.
Hormone therapy is the broad category. “Bioidentical” means the hormone has the same molecular structure as one your body makes. It tells you nothing by itself about manufacturing quality, FDA review, dosage form, safety, or whether that product is better for you.
These include FDA-approved estradiol and micronized progesterone products. FDA review covers quality, labeling, safety, and effectiveness for specific uses. “Bioidentical” and “FDA-approved” can describe the same product.
Compounded hormones may be considered when a woman has an individual medical need that cannot be met by an available FDA-approved hormone treatment—such as an allergy to an ingredient, the need for a different strength, or a medically necessary dosage form that is not commercially available. When an FDA-approved option can meet her needs, it is generally preferred because it has been evaluated for consistent strength, quality, safety, and effectiveness. Treatment should be individualized through a physician-led evaluation rather than based solely on standardized formulas or saliva hormone testing.
If you currently use a compounded cream: this information is not a reason to feel alarmed or to stop or change a prescribed treatment. A compounded prescription can be appropriate when it was selected for your individual medical needs and is monitored by your physician. Bring any questions about the formulation, dose, or monitoring to the clinician who prescribed it.
No label determines the best option by itself. “Bioidentical,” “FDA-approved,” and “compounded” describe different features of a therapy. Being compounded does not by itself mean that a prescription is inappropriate. The best choice depends on the hormone, dose, route, formulation, your medical history, and physician evaluation.
You can be in perimenopause even while your periods are still coming. Your cycle may change—or sleep, temperature, mood, or concentration may change first. Menopause is diagnosed after 12 consecutive months without a period when no other cause explains it. Hormone levels can swing during the transition, so one laboratory value rarely tells the whole story. For a fuller discussion of treatment options, read our guide to hormone replacement therapy for women.
A hot flash may interrupt a meeting; a night sweat may wake you soaked at 2 a.m. These are vasomotor symptoms, and they are closely linked to the menopause transition. Systemic hormone therapy can work very well for them, but only after your individual benefits and risks are reviewed.
If night sweats keep waking you, treating them may help your sleep. But sleep apnea, depression, anxiety, medications, thyroid disease, and other conditions can look similar. The missing-word or “brain fog” feeling is real, yet hormone therapy is not a universal treatment for memory, mood, or an independent sleep disorder.
Vaginal dryness, burning, sex that has become painful, urinary urgency, or recurrent urinary symptoms can be part of genitourinary syndrome of menopause (GSM). If these are your main symptoms, local treatment may be enough; you may not need hormones throughout your whole body.
Sexual desire can change because of pain, relationship factors, medication, stress, sleep, depression, hormonal changes—or several things at once. Hormone therapy may help when discomfort is driving the problem. Low desire is more complicated, and a prescription should not be the automatic conclusion.
Estrogen helps maintain bone. Systemic therapy prevents bone loss and reduces fracture risk while it is used, but that does not make it the right osteoporosis treatment for everyone.
You may notice that weight settles differently or that maintaining muscle takes more effort during the menopause years. Those changes are real, but hormone therapy is not an FDA-approved weight-loss treatment.
Your periods may still be coming, but your sleep, temperature, mood, or concentration feels different. We look at the pattern, consider pregnancy and other possible causes, and discuss whether testing or treatment would add useful information. A single hormone number rarely settles the question.
A flash in public or another soaked night can become hard to work around. Systemic hormone therapy is highly effective for these symptoms, and nonhormone options also exist. The choice depends on expected relief and your breast, uterine, clotting, stroke, and cardiovascular considerations.
If dryness, burning, painful sex, or urinary symptoms are the problem, say so plainly. We can ask whether GSM is involved and whether moisturizers, lubricants, local vaginal estrogen, vaginal DHEA, ospemifene, pelvic care, or another targeted approach fits.
Persistent symptoms do not automatically mean you need more hormone. We first check the diagnosis, product, route, dose, how it is being used, side effects, and other possible causes.
Your concern is reasonable, especially if cancer, a clot, or heart disease has touched your family. Bring your personal and family history. Risk changes with age, timing, route, dose, duration, formulation, and whether estrogen is used alone or with a progestogen.
Start with a complete sexual-health assessment, not a testosterone number alone. Evidence supports a carefully monitored trial primarily for selected postmenopausal women with hypoactive sexual desire disorder (HSDD). It is not a universal treatment for menopause symptoms, fatigue, weight, or cognition.
| Clinical goal | Potential approach | Important limitation |
|---|---|---|
| Hot flashes/night sweats | Systemic menopausal hormone therapy may be considered | Requires individualized risk assessment |
| Vaginal/GSM symptoms | Local vaginal therapy may be appropriate | Systemic treatment is not always necessary |
| Endometrial protection | Adequate progestogen is generally needed with systemic estrogen in a woman with a uterus | Regimen depends on clinical circumstances |
| Distressing low desire/HSDD | Testosterone may be considered for carefully selected postmenopausal women | Off-label in the U.S.; not a universal libido treatment |
| Bone health | Systemic estrogen prevents bone loss while used | Not synonymous with treating every osteoporosis patient |
Estradiol is the principal estrogen before menopause. Systemic estradiol is available in oral and transdermal FDA-approved forms. Route matters: transdermal therapy avoids first-pass liver metabolism and may have a more favorable clotting-risk profile for some patients.
Unopposed systemic estrogen can stimulate the uterine lining. A woman with an intact uterus generally needs adequate endometrial protection unless a specific specialist-managed exception applies.
Low-dose vaginal estrogen has limited systemic absorption compared with systemic therapy and can be effective for GSM. Women with a history of estrogen-dependent cancer should involve their oncology and gynecology teams in shared decision-making.
For many healthy people with bothersome symptoms who are younger than 60 or within 10 years of menopause onset, the benefit-risk balance is favorable. That is a population-level finding, not a promise about you. Your own history still decides the conversation.
Hormone therapy should not be promoted to prevent heart disease, stroke, dementia, or aging; guarantee weight loss; reverse every mood or cognitive complaint; restore hormones to a younger “optimal” target; or prevent cancer. Treatment aims should be specific, measurable, and periodically reassessed.
Before deciding anything, we listen to the pattern: your cycles, symptoms, bleeding, prior treatment, medications, and what is changing day to day. Pregnancy assessment when relevant, uterus and ovary status, cancer history, cardiovascular and clot risk, blood pressure, age-appropriate screening, and targeted laboratory testing help rule in—or rule out—appropriate options.
After age 45, menopause is often a clinical diagnosis based on your history. FSH and estradiol can fluctuate during perimenopause, so normal-looking bloodwork does not mean your experience is imaginary—and symptoms do not automatically mean you need hormones. Saliva and urine tests are not recommended to “customize” menopausal hormone dosing.
Monitoring focuses on symptom response, side effects, bleeding, blood pressure, adherence, new diagnoses, and whether the lowest effective dose and appropriate route still meet the goal. New postmenopausal bleeding needs prompt evaluation.
The only evidence-based indication endorsed by the global consensus statement is treatment of hypoactive sexual desire disorder (HSDD) in postmenopausal women after a formal biopsychosocial assessment.
There is no FDA-approved testosterone formulation specifically for cisgender women in the United States. Use is off-label and requires informed consent about benefits, uncertainties, and monitoring.
Testosterone should not be marketed as a universal treatment for fatigue, cognition, mood, weight loss, muscle gain, hot flashes, disease prevention, or reversing aging.
Potential effects include acne and increased facial/body hair; supraphysiologic exposure can cause voice change, scalp hair loss, clitoral enlargement, and other androgenic effects. Pellets and injections that produce high levels should be avoided. Long-term breast and cardiovascular safety remain uncertain.
You do not need to decide whether you want hormones before the appointment. Start with what has changed: symptoms, cycle pattern, medical history, prior treatments, medications, screening, concerns, and goals.
Dr. Mackey reviews your full clinical picture and orders or reviews testing when it can answer a useful question. Laboratory values are interpreted in context, not treated as a verdict.
If treatment is appropriate, you will discuss formulation, route, dose, uterine protection, likely benefits, limitations, and alternatives. Choosing not to use hormones remains a valid outcome.
Your response, side effects, bleeding, goals, and new health information guide what happens next. Treatment is reassessed rather than assumed to continue unchanged.
NovaGenix is located in Jupiter and serves Palm Beach County and South Florida. Eligible Florida patients may be evaluated by telemedicine when legally and clinically appropriate; laboratory or in-person requirements may still apply.
BHRT is not a separate risk-free category. Some conventional FDA-approved products contain bioidentical estradiol or micronized progesterone. The clinically meaningful questions are the hormone, indication, dose, route, regulatory status, and your individual risks.
If you have a uterus and use systemic estrogen, you generally need adequate progestogen to protect the endometrium. Local low-dose vaginal estrogen is different; requirements depend on the product and clinical context.
A compounded prescription can be individualized in strength, dosage form, or ingredients when there is a clinically appropriate reason. FDA-approved products also come in multiple hormones, doses, and routes and can often meet individual needs. The right choice is the one your physician determines is appropriate after reviewing your history, treatment goals, and available options.
They sometimes help when the diagnosis is uncertain or menopause occurs early, but fluctuating levels can make a single result misleading. In many women over 45, cycle and symptom history guide diagnosis.
No. Low-dose local vaginal estrogen is designed to treat vaginal and urinary tissues with much lower systemic exposure than systemic therapy. Some vaginal rings are systemic, so the exact product matters.
The relationship varies by regimen, duration, and baseline risk. Estrogen-alone and combined estrogen-progestogen evidence differ. A personalized discussion is more accurate than a blanket yes or no.
Seek specialist input for unexplained or postmenopausal bleeding, complex pelvic symptoms, premature ovarian insufficiency, cancer history, high clot or cardiovascular risk, uncertain diagnosis, or symptoms that do not respond as expected.
Content is for education and does not replace individualized medical advice.
You do not need to arrive having chosen hormone therapy. Bring your symptoms, history, concerns, and goals. Dr. Mackey will help determine whether hormones, a nonhormone approach, targeted local treatment, additional evaluation, or no treatment is the most reasonable next step.
